Generic drug bill
Legislation to increase FDA enforcement authority is expected to be introduced on May 15 by Rep. Dingell (D-Mich.), whose House Oversight Subcommittee has investigated the generic drug scandal for nearly two years. The measure will be referred to the Health Subcommittee, chaired by Rep. Waxman (D-Calif.), who will not be a cosponsor. Waxman reportedly is concerned that the bill's sanctions solely target the generic and not the brandname industry and that the HHS Inspector General's enforcement authority might supersede FDA's regarding FD&C Act felony violations.
You may also be interested in...
The company has identified 600 sites of care to treat Alzheimer's patients with aducanumab in the US and is confident on its pricing strategy, management said.
The robotic surgery company recorded $1.29bn in first-quarter revenue, an 18% year-over-year increase. Worldwide da Vinci procedures were up 16% as surgical volumes recovered from the pandemic.
The Department of Toxic Substances Control does not identify specific chemicals of concern in its 2021-2023 Priority Product Draft Work Plan, but says it is focusing on ingredients and endpoints associated with children, women of childbearing age, communities of color and aquatic impacts.